NZ738043B2 - Nanoparticle compositions for sustained therapy - Google Patents

Nanoparticle compositions for sustained therapy Download PDF

Info

Publication number
NZ738043B2
NZ738043B2 NZ738043A NZ73804316A NZ738043B2 NZ 738043 B2 NZ738043 B2 NZ 738043B2 NZ 738043 A NZ738043 A NZ 738043A NZ 73804316 A NZ73804316 A NZ 73804316A NZ 738043 B2 NZ738043 B2 NZ 738043B2
Authority
NZ
New Zealand
Prior art keywords
dra
drb3
relevant antigen
hla
drb1
Prior art date
Application number
NZ738043A
Other versions
NZ738043A (en
Inventor
Pedro Santmaria
Original Assignee
Uti Limited Partnership
Filing date
Publication date
Application filed by Uti Limited Partnership filed Critical Uti Limited Partnership
Priority claimed from PCT/IB2016/000691 external-priority patent/WO2016198932A2/en
Publication of NZ738043A publication Critical patent/NZ738043A/en
Publication of NZ738043B2 publication Critical patent/NZ738043B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof. In particular, the invention provides a complex comprising a nanoparticle coupled via a less than 5 kDa PEG linker with maleimide end to a plurality of antigen relevant MHC class II complexes, where the 1nm-100nm nanoparticle core comprises iron oxide and where the pMHCII density per nanoparticle is 0.4 - 50 pMHC/100nm^2 and where the pMHCII complexes are from a list.

Claims (25)

What is claimed is:
1. A complex comprising a nanoparticle core coupled, through a polyethylene glycol (PEG) linker, to a plurality of autoimmune disease or inflammation-relevant antigen-MHC class II (pMHCII) complexes, wherein the nanoparticle core comprises iron oxide, has a diameter from 1 nm to 100 nm, and the pMHCIIs are coupled to a maleimide functionalized end of the PEG linker, wherein a non-maleimide functionalized end of the polyethylene glycol of the PEG linker ses one or more of a C1-C3 alkoxy group, C(O)R-, -R10C(O)NHR-, - R10OC(O)R-, or -R10C(O)OR-, wherein each R is independently H or C1-C6 alkyl and wherein each R10 is independently a bond or C1-C6 alkyl, wherein the PEG linker is less than 5 kilodaltons in molecular weight, and n the pMHCII density per nanoparticle is from 0.4 pMHC/100 nm2 to 12 pMHC/100 nm2 of the surface area of the nanoparticle, and n the valency of the ity of pMHCII complexes per nanoparticle core is from 10:1 to 100:1, and wherein the pMHCII complexes comprise HLA-DRB1/DRA, HLA-DRB3/DRA, HLA-DRB4/DRA, B5/DRA, HLA-DQA1/HLA-DQB1, or HLA-DPB1/HLADPA1.
2. The complex of claim 1, wherein the nanoparticle core further comprises an outer layer comprising a radable sugar or other r on the nanoparticle core.
3. The complex of claim 1 or 2, wherein the nanoparticle core ses a diameter from 5 nm to 50 nm.
4. The complex of any one of claims 1 to 3, wherein the autoimmune disease, or mation-relevant antigen is one or more of the group consisting of: an asthma-relevant antigen, a diabetes-relevant antigen, a pre-diabetes relevant n, a multiple sclerosisrelevant antigen, an allergic asthma-relevant antigen, a primary biliary cirrhosis-relevant antigen, a cirrhosis-relevant antigen, a Neuromyelitis optica spectrum disorder (Devic’s disease, NMO)-relevant antigen, an mune encephalitis-relevant antigen, an antigen relevant to autoantibody-mediated neurological syndromes, a Stiff Man syndrome-relevant n, a paraneoplastic disease-relevant antigen, antigens relevant to other es of the central and peripheral nervous systems, a Pemphigus vulgaris-relevant antigen, inflammatory bowel disease (IBD)-relevant antigen, Crohn’s disease-relevant antigen, Ulcerative Colitis- relevant antigen, an arthritis-relevant antigen, a Rheumatoid Arthritis-relevant antigen, a systemic lupus erythematosus (SLE)-relevant antigen, a Celiac Disease nt antigen, a psoriasis-relevant n, an Alopecia Areata-relevant antigen, an Acquired Thrombocytopenic a-relevant antigen, an autoimmune cardiomyopathy-relevant antigen, an idiopathic dilated cardiomyopathy (IDCM)-relevant antigen, a Myasthenia Gravis-relevant antigen, an Uveitis-relevant antigen, an Ankylosing Spondylitis-relevant antigen, a Grave’s Disease-relevant antigen, a Hashimoto’s thyroiditis-relevant antigen, an Immune Mediated Myopathies-relevant antigen, an anti-phospholipid syndrome (ANCA+)- relevant antigen, an atherosclerosis-relevant antigen, a scleroderma-relevant antigen, an autoimmune hepatitis-relevant antigen, a dermatomyositis-relevant antigen, a chronic obstructive pulmonary disease-relevant antigen, a spinal cord -relevant antigen, a traumatic injury-relevant antigen, a tobacco-induced lung destruction-relevant antigen, a Chronic Obstructive ary e (COPD)-relevant n, a lung emphysemarelevant antigen, a sing cholangitis-relevant antigen, a peripheral neuropathy-relevant antigen, a narcolepsy-relevant antigen, a Goodpasture Syndrome-relevant antigen, a Kawasaki´s Disease-relevant antigen, an autoimmune uveitis-relevant antigen, a colitisrelevant n, an emphysema-relevant antigen, a gus-relevant antigen, a pemphigus folliaceus-relevant antigen, an arthritis-relevant antigen, a Sjogren’s Syndrome-relevant n, an ssociated vasculitis-relevant antigen, a primary sclerosing cholangitisrelevant antigen, an adipose tissue inflammation/diabetes type II-relevant antigen, and an obesity associated adipose tissue inflammation/insulin resistance-relevant antigen.
5. The complex of any one of claims 1 to 4, wherein the pMHCII complex is covalently coupled to the nanoparticle core by the linker.
6. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a Celiac e-relevant antigen and the pMHC x is selected from the group of: aGlia57HLA-DQA1*0501/HLA-DQB1*0201, aGlia62HLADQA1 *0501/HLA-DQB1*0201, aGlia217HLA-DQA1*0501/HLA-DQB1*0302, or aGlia217HLA-DQA1*03/HLA-DQB1*0302.
7. The x of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a y biliary gitis-relevant antigen and pMHC complex is selected from the group of: PDC-E2122HLA-DRB4*0101/DRA, PDC-E2249- 262-HLA-DRB4*0101/DRA, PDC-E2249HLA-DRB1*0801/DRA, PDC-E2629HLA- DRB1*0801/DRA, PDC-E272HLA-DRB3*0202/DRA, PDC-E2353HLADRB3 *0202/DRA, PDC-E2422HLA-DRB3*0202/DRA, PDC-E2629HLADRB4 *0101/DRA, PDC-E280HLA-DRB5*0101/DRA, PDC-E2353HLADRB5 *0101/DRA, or PDC-E2535HLA- DRB5*0101/DRA.
8. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is an autoimmune hepatitis-relevant antigen and the pMHC complex is selected from the group of: CYP2D6193HLA-DRB1*0301/DRA, CYP2D676HLA-DRB1*0301/DRA, CYP2D6293HLA-DRB1*0301/DRA, CYP2D6313HLA-DRB1*0301/DRA, CYP2D6393HLA-DRB1*0301/DRA, 199HLA-DRB1*0401/DRA, CYP2D6450HLA-DRB1*0401/DRA, CYP2D6301HLA-DRB1*0401/DRA, CYP2D6452HLA-DRB1*0701/DRA, CYP2D659HLA-DRB1*0701/DRA, CYP2D6130HLA-DRB1*0701/DRA, CYP2D6193HLA-DRB1*0701/DRA, CYP2D6305HLA-DRB1*0701/DRA, 131HLA-DRB3*0202/DRA, CYP2D6216HLA-DRB3*0202/DRA, 238HLA-DRB3*0202/DRA, 199HLA-DRB4*0101/DRA, CYP2D6235HLA-DRB4*0101/DRA, CYP2D6293HLA-DRB4*0101/DRA, CYP2D6238HLA-DRB5*0101/DRA, CYP2D6381HLA-DRB5*0101/DRA, CYP2D6429HLA-DRB5*0101/DRA, SLA334HLA-DRB1*0301/DRA, SLA196- A-DRB1*0301/DRA, SLA115HLA-DRB1*0301/DRA, SLA373HLADRB1 *0301/DRA, SLA186HLA-DRB1*0301/DRA, SLA317HLADRB1 *0401/DRA, SLA171HLA-DRB1*0401/DRA, SLA417HLADRB1 *0401/DRA, SLA359HLA-DRB1*0701/DRA, SLA215HLADRB1 *0701/DRA, SLA111HLA- DRB1*0701/DRA, SLA110HLADRB3 *0202/DRA, SLA299HLA-DRB3*0202/DRA, SLA342HLADRB3 *0202/DRA, SLA49HLA-DRB4*0101/DRA, SLA119HLADRB4 *0101/DRA, SLA260HLA-DRB4*0101/DRA, SLA26HLADRB5 DRA, SLA86HLA-DRB5*0101/DRA, and SLA331HLADRB5 *0101/DRA.
9. A composition comprising a plurality of complexes of any one of claims 1 to 8 and a pharmaceutically acceptable r.
10. The complex of any one of claims 1 to 5 or the composition of claim 10 for use in the treatment of pre-diabetes, multiple sclerosis, allergic asthma, y biliary cirrhosis, cirrhosis, yelitis optica spectrum disorder (Devic’s e, NMO), autoimmune encephalitis, autoantibody-mediated neurological syndromes, a Stiff Man syndrome, oplastic disease, other diseases of the l and peripheral nervous systems, Pemphigus vulgaris, inflammatory bowel disease, Crohn’s disease, Ulcerative Colitis, arthritis, toid Arthritis, systemic lupus erythematosus (SLE), Celiac Disease, psoriasis, Alopecia , Acquired ocytopenic Purpura, autoimmune cardiomyopathy, idiopathic d cardiomyopathy (IDCM), Myasthenia Gravis, Uveitis, Ankylosing Spondylitis, Grave’s Disease, Hashimoto’s thyroiditis, Immune Mediated Myopathies, anti-phospholipid syndrome (ANCA+), sclerosis, scleroderma, mune hepatitis, dermatomyositis, chronic obstructive pulmonary disease, a spinal cord injury, tic injury, tobacco-induced lung destruction, Chronic Obstructive Pulmonary Disease (COPD), lung emphysema, sclerosing cholangitis, peripheral athy, narcolepsy, Goodpasture Syndrome, Kawasaki´s Disease, autoimmune uveitis, colitis, emphysema, pemphigus, pemphigus folliaceus, Sjogren’s Syndrome, ssociated vasculitis, primary sclerosing cholangitis-relevant antigen, adipose tissue inflammation/diabetes type II, or obesity associated adipose tissue inflammation/insulin resistance.
11. Use of the complex of any one of claims 1 to 5 for the manufacture of a medicament for the ent of pre-diabetes, multiple sclerosis, allergic asthma, primary biliary cirrhosis, cirrhosis, Neuromyelitis optica spectrum disorder (Devic’s disease, NMO), autoimmune encephalitis, autoantibody-mediated neurological syndromes, a Stiff Man syndrome, paraneoplastic disease, other diseases of the central and peripheral nervous systems, Pemphigus vulgaris, inflammatory bowel disease, Crohn’s disease, Ulcerative Colitis, arthritis, Rheumatoid Arthritis, systemic lupus erythematosus (SLE), Celiac Disease, psoriasis, Alopecia Areata, Acquired Thrombocytopenic a, autoimmune cardiomyopathy, idiopathic dilated cardiomyopathy (IDCM), Myasthenia Gravis, Uveitis, Ankylosing Spondylitis, s Disease, Hashimoto’s thyroiditis, Immune Mediated hies, anti-phospholipid syndrome (ANCA+), atherosclerosis, scleroderma, autoimmune hepatitis, dermatomyositis, chronic obstructive pulmonary disease, a spinal cord injury, traumatic , tobacco-induced lung destruction, c Obstructive Pulmonary Disease (COPD), lung emphysema, sclerosing cholangitis, peripheral neuropathy, narcolepsy, Goodpasture Syndrome, Kawasaki´s Disease, autoimmune uveitis, colitis, emphysema, gus, pemphigus ceus, Sjogren’s Syndrome, ANCA-associated vasculitis, primary sclerosing gitis-relevant antigen, adipose tissue mation/diabetes type II, or obesity associated adipose tissue inflammation/insulin resistance.
12. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a type I diabetes-relevant antigen and the pMHC complex is selected from the group of: PPI76-90(K88S)-HLA-DRB1*0401/DRA, IGRP13HLADRB1 *0301/DRA, GAD555HLA-DRB1*0401/DRA, GAD555-567(557I)-HLADRB1 *0401/DRA, IGRP23HLA-DRB1*0401/DRA, B24-C36-HLA-DRB1*0301/DRA, or PPI76HLA-DRB1*0401/DRA.
13. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant n is a multiple sclerosis-relevant antigen and the pMHC complex is selected from the group of: MBP86HLA-DRB1*1501/DRA, 101-HLADRB5 *0101/DRA, MOG38HLA-DRB4*0101/DRA, MOG97-109(E107S)-HLADRB1 *0401/DRA, MOG203HLA-DRB3*0101/DRA, PLP54HLA-DRB3*0101/DRA, PLP94HLA-DRB1*0301/DRA, PLP250HLA-DRB4*0101/DRA, MPB13HLADRB5 *0101/DRA, MPB83HLA-DRB5*0101/DRA, MPB111HLA-DRB5*0101/DRA, MPB146HLA-DRB5*0101/DRA, MOG223HLA-DRB3*0202/DRA, MOG6HLADRB5 DRA, PLP88HLA-DRB3*0202/DRA, or PLP139HLADRB5 *0101/DRA.
14. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a gus foliaceus and/or pemphigus vulgaris-relevant antigen and the pMHC complex is ed from the group of: DG1216HLADRB1 *0101/DRA, DG1216HLA-DRB1*0102/DRA, 111-HLA-DRB1*0402/DRA, HLA-DRB1*0402/DRA, DG3251HLA-DRB1*0401/DRA, DG3441HLADRB1 *0402/DRA, DG3351HLA-DRB3*0202/DRA, DG3453HLA-DRB3*0202/DRA, DG3540HLA-DRB3*0202/DRA, DG3280HLA-DRB4*0101/DRA, DG3326HLADRB4 *0101/DRA, DG3367HLA-DRB4*0101/DRA, DG313HLA-DRB5*0101/DRA, DG3323HLA-DRB5*0101/DRA, DG3438HLA-DRB5*0101/DRA, DG148HLADRB3 *0202/DRA, DG1206HLA-DRB3*0202/DRA, DG1363HLA-DRB3*0202/DRA, DG13HLA-DRB4*0101/DRA, DG1192HLA-DRB4*0101/DRA, DG1326HLADRB4 *0101/DRA, DG11HLA-DRB5*0101/DRA, 49-HLA-DRB5*0101/DRA, or DG1325HLA-DRB5*0101/DRA.
15. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a neuromyelitis optica spectrum disorder-relevant antigen and the pMHC complex is selected from the group of: AQP4129HLA-DRB1*0101/DRA, AQP4284HLA-DRB1*0301/DRA, AQP463HLA-DRB1*0301/DRA, AQP4129HLADRB1 *0401/DRA, or AQP439HLA-DRB1*1501/DRA.
16. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is an allergic asthma-relevant antigen and the pMHC complex is selected from the group of: DERP30–HLA-DRB1*0101/DRA, DERP30 -HLADRB1 *1501/DRA, DERP1171-185 – HLA-DRB1*1501/DRA, DERP124 –HLADPB1 *0401/DRA, DERP40 -HLA-DRB1*0101/DRA; DERP40-HLADRB1 *1501/DRA, or 107-121–HLA-DRB1*0301/DRA.
17. The complex of any one of claims 1 to 5, n the autoimmune disease- or inflammation-relevant antigen is a COPD and/or emphysema-relevant antigen and the pMHC x is selected from the group of: elastin89HLA-DRB3*0101/DRA, n698 HLA-DRB5*0101/DRA, elastin8HLA-DRB5*0101/DRA, elastin94HLADRB5 *0101/DRA, elastin13HLA-DRB4*0101/DRA, n695HLADRB4 *0101/DRA, elastin563HLA-DRB4*0101/DRA, elastin558HLADRB4 *0101/DRA, elastin698HLA-DRB5*0101/DRA, elastin566HLADRB3 *0202/DRA, or elastin645HLA-DRB3*0202/DRA.
18. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or mation-relevant antigen is a psoriasis-relevant antigen and the pMHC complex is selected from the group of: 4HLA-DRB3*0101/DRA, Cap1834HLADRB3 *0101/DRA, Cap1847HLA-DRB3*0101/DRA, Cap18151HLA - DRB4*0101/DRA, Cap18149HLA-DRB5*0101/DRA, Cap18152HLADRB5 *0101/DRA, Cap18131HLA-DRB5*0101/DRA, Cap1824HLADRB3 *0202/DRA, ADMTSL5245HLA-DRB3*0101/DRA, ADMTSL5267HLADRB3 *0101/DRA, ADMTSL5372HLA-DRB3*0101/DRA, 5289HLADRB4 *0101/DRA, ADMTSL5396HLA-DRB4*0101/DRA, ADMTSL5433HLADRB4 *0101/DRA, ADMTSL5142HLA-DRB5*0101/DRA, ADMTSL5236HLADRB5 DRA, ADMTSL5301HLA-DRB5*0101/DRA, ADMTSL5203HLADRB3 *0202/DRA, ADMTSL5404HLA-DRB3*0202/DRA, or ADMTSL5433HLADRB3 *0202/DRA.
19. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a uveitis-relevant n and the pMHC complex is selected from the group of: arrestin199HLA-DRB3*0101/DRA, arrestin77HLADRB3 *0101/DRA, arrestin250HLA-DRB3*0101/DRA, arrestin172HLADRB4 *0101/DRA, arrestin354HLA-DRB4*0101/DRA, arrestin239HLADRB4 *0101/DRA, arrestin102HLA-DRB5*0101/DRA, in59HLA-DRB5*0101, arrestin280HLA-DRB5*0101, arrestin291HLA-DRB1*0301/DRA, arrestin195HLADRB3 *0202/DRA, arrestin199HLA-DRB3*0202/DRA, or arrestin200HLADRB3 *0202/DRA.
20. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a Sjögren Syndrome-relevant antigen and the pMHC x is selected from the group of: 7HLA-DRB1*0301/DRA, RO60523 HLA-DRB1*0301/DRA, RO60243HLA-DRB1*0301/DRA, RO60484HLADRB3 *0101/DRA, RO60347HLA-DRB3*0101/DRA, RO60369HLADRB3 *0101/DRA, RO60426HLA-DRB4*0101/DRA, RO60267HLADRB4 *0101/DRA, RO60178HLA-DRB4*0101/DRA, RO60358HLADRB5 *0101/DRA, RO60358HLA-DRB4*0101/DRA, RO60221HLADRB5 *0101/DRA, RO60221HLA-DRB4*0101/DRA, RO60318HLADRB5 *0101/DRA, RO60318HLA-DRB4*0101/DRA, RO60407HLADRB4 *0101/DRA, RO60407HLA-DQA1*0501/HLA-DQB1*0201, RO60459HLADRB4 DRA, RO60459HLA-DQA1*0501/HLA-DQB1*0201, RO60318HLADQA1 HLA-DQB1*0201, RO6051HLA-DRB3*0202/DRA, RO60312HLADRB3 DRA, RO60347HLA-DRB3*0202/DRA, LA241HLA-DRB1*0301/DRA, LA101HLA-DRB1*0301/DRA, LA153HLA-DRB1*0301/DRA, LA178HLADRB3 *0101/DRA, LA19HLA-DRB3*0101/DRA, LA37HLA-DRB3*0101/DRA, LA133- 147-HLA-DRB4*0101/DRA, LA50HLA-DRB4*0101/DRA, 6-HLA- DRB4*0101/DRA, LA153HLA-DRB5*0101/DRA, LA83HLA-DRB5*0101/DRA, LA136HLA-DRB5*0101/DRA, LA297HLA-DQA1*0501/HLA-DQB1*0201, LA59 HLA-DQA1*0501/HLA-DQB1*0201, LA59HLA-DRB4*0101/DRA, LA151HLADQA1 *0501/HLA-DQB1*0201, LA151HLA-DRB4*0101/DRA, LA297HLADRB4 *0101/DRA, LA50HLA-DRB3*0202/DRA, LA86HLA-DRB3*0202/DRA, or LA154HLA-DRB3*0202/DRA.
21. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is a derma-relevant antigen and the pMHC complex is selected from the group of: TOP1346HLA-DRB3*0101/DRA, TOP1420HLADRB3 *0101/DRA, TOP1750HLA-DRB3*0101/DRA, TOP1419HLADRB4 *0101/DRA, TOP1591HLA-DRB4*0101/DRA, TOP1695HLADRB4 *0101/DRA, TOP1305HLA-DRB5*0101/DRA, TOP1346HLADRB5 *0101/DRA, TOP1419HLA-DRB5*0101/DRA, TOP1420HLADRB3 *0202/DRA, TOP1425HLA-DRB3*0202/DRA, 4HLADRB3 *0202/DRA, CENP-C297HLA-DRB3*0101/DRA, CENP-C857HLADRB3 *0101/DRA, CENP-C887HLA-DRB3*0101/DRA, CENP-C212HLADRB4 *0101/DRA, CENP-C643HLA-DRB4*0101/DRA, CENP-C832HLADRB4 *0101/DRA, CENP-C167HLA-DRB5*0101/DRA, CENP-C246HLADRB5 *0101/DRA, CENP-C846HLA-DRB5*0101/DRA, CENP-C149HLADRB3 DRA, CENP-C833HLA-DRB3*0202/DRA, or CENP-C847HLADRB3 *0202/DRA.
22. The complex of any one of claims 1 to 5, wherein the mune disease- or inflammation-relevant antigen is an anti-phospholipid syndrome-relevant antigen and the pMHC complex is ed from the group of: APOH235HLA-DRB3*0101/DRA, 6HLA-DRB3*0101/DRA, APOH237HLA-DRB3*0101/DRA, APOH295 HLA-DRB3*0101/DRA, APOH28HLA-DRB4*0101/DRA, APOH173HLADRB4 *0101/DRA, APOH264HLA-DRB4*0101/DRA, 5HLADRB4 *0101/DRA, APOH49HLA-DRB5*0101/DRA, APOH269HLADRB5 *0101/DRA, APOH295HLA-DRB5*0101/DRA, APOH321HLADRB3 *0202/DRA, APOH322HLA-DRB3*0202/DRA, or APOH324HLADRB3
23. The complex of any one of claims 1 to 5, wherein the autoimmune e- or inflammation-relevant antigen is an ANCA-associated vasculitis-relevant n and the pMHC complex is selected from the group of: MPO506HLA-DRB3*0101/DRA, MPO302- 316-HLA-DRB3*0101/DRA, MPO7HLA-DRB3*0101/DRA, MPO689HLA- DRB4*0101/DRA, MPO248HLA-DRB4*0101/DRA, MPO444HLADRB4 *0101/DRA, MPO513HLA-DRB5*0101/DRA, MPO97HLA-DRB5*0101/DRA, MPO616HLA-DRB5*0101/DRA, MPO462HLA-DRB3*0202/DRA, MPO617HLA- DRB3*0202/DRA, MPO714HLA-DRB3*0202/DRA, PRTN344HLADRB3 *0101/DRA, PRTN3234HLA-DRB3*0101/DRA, PRTN359HLA DRB3*0101/DRA, PRTN359HLA-DRB5*0101/DRA, PRTN3117HLADRB4 *0101/DRA, PRTN3164HLA-DRB4*0101/DRA, PRTN371HLADRB4 *0101/DRA, PRTN3241HLA-DRB5*0101/DRA, PRTN3183HLADRB5 *0101/DRA, PRTN362HLA-DRB3*0202/DRA, PRTN3118HLADRB3 *0202/DRA, or 39HLA-DRB3*0202/DRA.
24. The complex of any one of claims 1 to 5, wherein the autoimmune disease- or mation-relevant antigen is a Stiff man syndrome-relevant antigen and the pMHC complex is selected from the group of: GAD212HLA-DRB1*0801/DRA, GAD555 HLA-DRB1*0801/DRA, or GAD297HLA-DRB1*0301/DRA.
25. The x of any one of claims 1 to 5, wherein the autoimmune disease- or inflammation-relevant antigen is an inflammatory bowel disease(IBD)-relevant antigen, a Crohn’s disease-relevant antigen, an ulcerative colitis-relevant antigen, and/or a colitisrelevant antigen, and the pMHC complex is selected from the group of: bacteroides integrase antigen183-197 - HLA-DRB3*0101/DRA, bacteroides integrase antigen146-160 - HLADRB3 *0101/DRA, bacteroides integrase antigen175-189 - HLA-DRB3*0101/DRA, bacteroides integrase antigen1-15 - HLA-DRB5*0101/DRA, bacteroides integrase antigen183-197 - HLADRB5 *0101/DRA, bacteroides integrase antigen183-197 - B3*0101/DRA, bacteroides integrase antigen30-44 - HLA-DRB5*0101/DRA, oides integrase antigen70-84 - HLA-DRB4*0101/DRA, bacteroides integrase n337-351 - HLA-DRB4*0101/DRA, oides integrase antigen171-185 - HLA-DRB4*0101/DRA, bacteroides integrase antigen4 HLA-DRB3*0202/DRA, bacteroides integrase antigen171-185 - HLA-DRB3*0202/DRA, bacteroides integrase antigen256-270 - HLA-DRB3*0202/DRA, Fla-X366-380 - HLADRB3 *0101/DRA, Fla-2/Fla-X164-178 - HLA-DRB3*0101/DRA, Fla-2/Fla-X261-275 - HLADRB5 *0101/DRA, Fla-X1-15 - HLA-DRB5*0101/DRA, Fla-X51-65 - HLADRB4 *0101/DRA, Fla-2/Fla-X269-283 - HLA-DRB4*0101/DRA, Fla-2/Fla-X4-18 - HLA- DRB3*0202/DRA, Fla-X261-275 - HLA-DRB3*0202/DRA, Fla-2/Fla-X271-285 - HLADRB3 *0202/DRA, -92 - HLA-DRB3*0101/DRA, YIDX78-92 - HLADRB4 *0101/DRA, YIDX93-107 - HLA-DRB3*0101/DRA, -112 - HLADRB5 *0101/DRA, YIDX23-37 - HLA-DRB5*0101/DRA, YIDX78-92 - HLADRB4 *0101/DRA, YIDX195-209 - HLA-DRB4*0101/DRA, YIDX22-36 - HLA- DRB3*0202/DRA, -94 - HLA-DRB3*0202/DRA, or YIDX101-115 - HLADRB3 *0202/DRA. None set by MYN MigrationNone set by MYN Unmarked set by MYN None set by MYN MigrationNone set by MYN Unmarked set by MYN 6% 1A .11ngI//WI//’ gum zig?? x {xxx/”fl, “‘“‘“‘-- “xv“ \\\\\».\\\\\\\V~é~\sx\\w\\H *\.\\\'".\\\
NZ738043A 2016-05-06 Nanoparticle compositions for sustained therapy NZ738043B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562157933P 2015-05-06 2015-05-06
US201562273953P 2015-12-31 2015-12-31
US201662296032P 2016-02-16 2016-02-16
PCT/IB2016/000691 WO2016198932A2 (en) 2015-05-06 2016-05-06 Nanoparticle compositions for sustained therapy

Publications (2)

Publication Number Publication Date
NZ738043A NZ738043A (en) 2024-11-29
NZ738043B2 true NZ738043B2 (en) 2025-03-04

Family

ID=

Similar Documents

Publication Publication Date Title
McGonagle et al. Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis
JP2015504419A5 (en)
JP2017079785A5 (en)
JP2006506465A5 (en)
CA2708942A1 (en) Compositions and methods for treatment of autoimmune and allergic diseases
AR126555A2 (en) HUMAN ONCOSTATIN M ANTIBODIES AND METHODS OF USE
JP2012517818A5 (en)
JP2020075926A5 (en)
JP2016515130A5 (en)
JP2008516970A5 (en)
CN111432831A (en) I L-2 mutant protein and application thereof
JP2012021001A5 (en)
JP2012520308A5 (en)
JP2013537414A5 (en)
JP2014529608A5 (en)
JP2014525752A5 (en)
WO2011006914A3 (en) Antagonists, uses & methods for partially inhibiting tnfr1
RU2016128557A (en) METHODS AND COMPOSITIONS RELATED TO p62 / SQSTM1 FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH INFLAMMATION
Chung et al. Meta‐analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis
WO2011158566A1 (en) Urethane (meth)acrylate resin composition and coating material using same
Wroński et al. The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought?
NZ738043A (en) Nanoparticle compositions for sustained therapy
CN104411325B (en) method for treating inflammation
Tomer et al. Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti‐CD4 monoclonal antibodies
Alahmari et al. Environmental risks for systemic sclerosis